Navigation Links
Auxilium Pharmaceuticals Announces Results from Three Year CORDLESS Extension Study in Dupuytren's Contracture
Date:6/30/2011

reated patient had a serious adverse event of a motor vehicle accident, which was considered unrelated to drug.
  • The adverse event profile of XIAFLEX treated joints through three years follow-up revealed no new long-term adverse events.
  • Of the 74 serious adverse events reported through three years of follow-up, none were considered related to XIAFLEX and none occurred in the treated finger.

  • "While I am very impressed with the three year recurrence rate of 35% using a 20 degree change to define recurrence, the surgical literature has often defined recurrence as a 30 degree change.  Using this definition, XIAFLEX demonstrates an even lower 22% recurrence rate at three years,” said Dr. Vincent Hentz, Professor Emeritus, Surgery - Plastic/Recon Surgery, Stanford Medical School.  “With this longer term data, I believe that treatment with XIAFLEX of Dupuytren’s patients’ palpable cords can provide durable outcomes with a very acceptable rate of recurrence in the majority of patients.”

    Recurrence with XIAFLEX as defined by greater than or equal to 30 degrees standard used in surgical literatureAlthough there is no standard methodology to measure recurrence, the literature(2,3,4), on surgical treatment does reference a definition of recurrence as a 30 degree worsening of contracture following an intervention.  XIAFLEX recurrence was defined in the AUX-CC-860 clinical study as a 20 degree change in the presence of a palpable cord.  In order to evaluate within the context of the existing surgical literature, the three year XIAFLEX data was examined using a criterion referenced in the literature.  Specifically, for this post hoc analysis, the definition of recurrence was (a) a joint contracture that was successfully treated (had previously achieved a reduction in contracture to five degrees or less at the Day 30 evaluation after the last injection of XIAFLEX) that subsequently increases
    '/>"/>

    SOURCE Auxilium Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9

    Related medicine technology :

    1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
    2. Auxilium Pharmaceuticals, Inc. Announces XIAFLEX(TM) Meets Primary Endpoint With Statistical Significance (p<0.001) in CORD I Pivotal Phase III Study for Dupuytrens Contracture
    3. BioSpecifics Technologies Corp. Announces Auxilium XIAFLEX® Update
    4. Auxilium Pharmaceuticals, Inc. Announces Initiation of XIAFLEX® Phase III Studies for Peyronies Disease
    5. Auxilium Pharmaceuticals, Inc. Announces Issuance of Patent for Clostridial Collagenase
    6. Auxilium Pharmaceuticals to Present at the 2010 Annual Credit Suisse Healthcare Conference
    7. Auxilium Pharmaceuticals Reports Preliminary Fourth Quarter 2010 Net Revenue and Announces 2011 XIAFLEX Revenue Guidance
    8. Auxilium Pharmaceuticals to Present at the 2011 Citi Annual Global Healthcare Conference
    9. Auxilium Pharmaceuticals to Present at the Cowen and Company 31st Annual Health Care Conference
    10. Auxilium Pharmaceuticals, Inc. Completes Enrollment of XIAFLEX® Phase III Double-Blind Studies for Peyronies Disease
    11. Auxilium Pharmaceuticals, Inc. and Asahi Kasei Pharma Corporation Enter Agreement to Develop, Commercialize and Supply XIAFLEX® In Japan
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:10/17/2014)... 2014  Training market researchers to spot and ... in today,s highly competitive global marketplace. As resources ... effectively and efficiently produce high performing analysts, regardless ... Effective training programs can help these ... internal clients by developing analysts who can drive ...
    (Date:10/17/2014)... -- Research and Markets  has announced the ... of China Dialysis Market, 2014-2018" report to ... 2013 version, this update Report provides detailed analysis ... the relevant effect in recent three years, and ... it analyzes Chinese private-owned hemodialysis services. In the ...
    (Date:10/17/2014)... BALTIMORE, Md. , Oct. 17, 2014 /PRNewswire-USNewswire/ ... Center for Medical Technology Policy: The ... from the FDA, public and private payers, medical ... representatives, clinicians, and other experts January 12, 2015 ... effectiveness and value of weight loss treatments.  Participants ...
    Breaking Medicine Technology:Effective Training Programs for Market Research Groups can Boost Overall Organizational Success 2Research and Development Prospect of China Dialysis Market, 2014-2018 2Research and Development Prospect of China Dialysis Market, 2014-2018 3Green Park Collaborative to Discuss Comparative Effectiveness and Value of Weight Loss Treatments 2
    (Date:10/20/2014)... DALLAS (PRWEB) October 20, 2014 It’s hard ... for many orphans and vulnerable children around the world, it’s ... by some people, many children are forced to walk barefoot ... for their families or play with their friends. , ... partnering with Air1 Radio in October to encourage ...
    (Date:10/19/2014)... and Hastings, a Phoenix personal injury law firm with ... area and across Arizona reports record demand in 2014 ... Statistics have indicated a steady increase in automobile accidents ... and Hastings has seen a steady increase in the ... injured through no fault of their own that is ...
    (Date:10/19/2014)... October 20, 2014 This report ... Partial Seizure, complete with comparative analysis at various ... action (MoA), route of administration (RoA) and molecule ... and press releases. It also reviews key players ... and special features on late-stage and discontinued projects. ...
    (Date:10/19/2014)... SweetDressy.com, a professional company of women’s dresses and ... evening dresses . All the company’s old and ... discount is up to 66 percent off. , ... fashion field. Its dress specialists are striving to make ... of the world. All the company’s items are unique, ...
    (Date:10/19/2014)... spondylitis is a systemic disease that causes inflammation ... have affected members of the ancient Egyptian royal ... Arthritis & Rheumatology , a journal of the ... finding instead a degenerative spinal condition called diffuse ... from the 18th to early 20th Dynasties. ...
    Breaking Medicine News(10 mins):Health News:Buckner Shoes for Orphan Souls® Garners Support from Air1 Radio 2Health News:Buckner Shoes for Orphan Souls® Garners Support from Air1 Radio 3Health News:Hastings And Hastings Reports Record Demand In 2014 For Legal Representation With Regard To Catastrophic Automobile Accidents 2Health News:Hastings And Hastings Reports Record Demand In 2014 For Legal Representation With Regard To Catastrophic Automobile Accidents 3Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 2Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 3Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 4Health News:Promotion For Beautiful Long Evening Dresses Launched By SweetDressy.com 2Health News:Mummy remains refute antiquity of ankylosing spondylitis 2
    ... , , TULSA, Okla., ... its service area across Oklahoma by partnering with several EMS providers ... 1st, 2009. , , Since the commercial ... 1.3 million people served by the Emergency Medical Services Authority (EMSA) ...
    ... finds more evidence in areas where more men ... -- High levels of persistent environmental chemicals are ... countries with high rates of male reproductive problems, ... endocrine-disrupting chemicals, or EDCs, are commonly found in ...
    ... , , EMERYVILLE, Calif., Sept. ... today announced that it will webcast an investor briefing on ... Speakers will review clinical data for Nexavar in breast cancer ... European Society for Medical Oncology (ESMO) Multidisciplinary Congress in Berlin. ...
    ... , LAKE FOREST, Ill., Sept. 24 ... pharmaceuticals, and Synerx Pharma, LLC, announced today the launch of ... Paladin Labs, Inc. , , (Logo: http://www.newscom.com/cgi-bin/prnh/20080702/AQW070LOGO ... to Bioniche,s product offering further broadens our base of niche ...
    ... introduction of statins to treat high cholesterol, the decline ... double that experienced by the poor. While statins ... health, their use may have contributed to expanding social ... research by Virginia W. Chang, MD, PhD, of the ...
    ... , , NEW ... market research report is available in its catalogue. , ... Market Assessment (Latest Data, Company Profiles, Implications for Immunoassays ... http://www.reportlinker.com/p0119228/H1N1-(Swine-Influenza)-Market-Assessment-(Latest-Data-Company-Profiles-Implications-for-Immunoassays-and-Molecular-Assays).html , , ...
    Cached Medicine News:Health News:Oklahoma Medics Embracing iB Web Service 2Health News:Environmental Chemicals May Affect Male Reproduction 2Health News:Bioniche Pharma and Synerx Pharma Launch Fomepizole Injection 2Health News:Reportlinker Adds H1N1 (Swine Influenza) Market Assessment (Latest Data, Company Profiles, Implications for Immunoassays and Molecular Assays) Report 2Health News:Reportlinker Adds H1N1 (Swine Influenza) Market Assessment (Latest Data, Company Profiles, Implications for Immunoassays and Molecular Assays) Report 3Health News:Reportlinker Adds H1N1 (Swine Influenza) Market Assessment (Latest Data, Company Profiles, Implications for Immunoassays and Molecular Assays) Report 4
    Incontinence Pessaries...
    Incontinence Dish - Stress Incontinence with mild prolapse. Incontinence Dish with support - Stress Incontinence with mild prolapse and mild cystocele...
    ... is designed for third degree ... as a cystocele and rectocele. ... both with and without drainage ... tie to aid in removal. ...
    ... Gellhorn Pessary is used for ... prolapse, or procidentia. It has ... and comes in nine sizes. ... easily folds over for insertion, ...
    Medicine Products: